National Cancer Institute, CDBL, NIH, Frederick, MD, USA.
Adv Exp Med Biol. 2018;1079:1-15. doi: 10.1007/5584_2018_175.
After progressive improvement in embryonic stem (ES) cell field, several studies have been conducted to explore the usage of ES cells in regenerative medicine. Unlimited self renewal and pluripoteny properties, combined with encouraging preclinical trials, remark that ES cell technology might be promising for clinical practice. ES cells, which can form three germ layers in vitro, are potential candidates to study development at the cellular and molecular level. Understanding the cell fate decision and differentiation processes during development might enable generating functional progenitor cells for tissue restoration. Progression in gene modifications and tissue engineering technology has facilitated the derivation of desired cells for therapy. Success in differentiation protocols and identification the regulatory pathways simplify the research for clinical applications. Although there are established protocols for cell differentiation in vitro and promising preclinical studies in vivo, many challenges need to be adressed before clinical translation. In this review, ES cells are discussed as a model of development in vitro and as a potential candidate for regenerative medicine. This review also dissusses current challenges for ES cell based therapy.
胚胎干细胞(ES 细胞)领域不断取得进展,此后开展了多项研究,旨在探索 ES 细胞在再生医学中的应用。ES 细胞具有无限自我更新和多能性,再加上令人鼓舞的临床前试验结果,表明 ES 细胞技术可能具有广阔的临床应用前景。ES 细胞在体外可形成三个胚层,是研究细胞和分子水平发育的潜在候选者。了解发育过程中的细胞命运决定和分化过程,可能有助于生成用于组织修复的功能祖细胞。基因修饰和组织工程技术的进步促进了所需细胞的治疗衍生。分化方案的成功和调控途径的确定简化了临床应用的研究。尽管已经建立了体外细胞分化的既定方案,并且在体内进行了有前景的临床前研究,但在临床转化之前,仍需要解决许多挑战。本综述讨论了 ES 细胞作为体外发育模型和再生医学的潜在候选者。本文还讨论了基于 ES 细胞治疗的当前挑战。